Rearch homepage new banner Nov 2013


Our expertise research and development spans the entire life-cycle of a medicine. We have capabilities in both small molecules and biologics. This allows us to search for solutions to unmet medical needs using both modalities, individually or in combination

Guangzhou Medical University & AstraZeneca: Advancing understanding of COPD in China

An IMED Collaboration Update

We’re working with Guangzhou Medical University, one of the world’s leading centres for research into respiratory disease, to advance the scientific understanding of Chronic Obstructive Pulmonary Disease (COPD). Our team had previously carried out COPD studies in many western countries and was interested in comparing earlier findings with those from China, where COPD prevalence is high and rising rapidly. Our aim is to find better ways of diagnosing and preventing incidence.

Download collaboration update (PDF 260kb)

Our leaders iconOur leaders

All Directors are collectively responsible for the success of AstraZeneca. Discover general information,  images and biographies of our Board of Directors.

Read more

Pipeline iconOur pipeline

AstraZeneca's pipeline is one of the most exciting in the industry. Download the latest version of our development pipeline.

Read more

Path to meds iconPath to new medicines

The discovery, development and commercialisation of a medicine is a complex process. Information on our path to new medicines and an interactive overview are available.

Read more

Neuro iconAZ Neuroscience

Visit our dedicated neuroscience site for more information on our research and partnering in the area.


Visit site

Open innovation iconOpen innovation

Visit our Open Innovation site to see how we collaborate to push the boundaries of science and deliver life-changing medicines

Visit site

LabTalk is AstraZeneca’s science-focused blog where you can hear from scientists, researchers and academics discussing novel ideas, research and innovation.

Targeting_escape_THM 9 October 2015

Targeting escape pathways to further personalise breast cancer treatment